Chikujee develops a full spectrum of products used primarily in oncology, cardiovascular diseases and critical care. Chikujee has created and developed its first oncology product for the treatment of metastatic breast cancer, using its’ proprietary nanobindi technology that will go in clinical trials by the end of 2008. This innovative approach may revolutionize the detection and treatment of cancer.

There are two major initiatives for its product development, of which one is based on its SEND^TM imaging probe platform for targeted diagnostics and TSDV^TM platform for cell specific targeting of therapeutic drugs.

1.1            NIDÄ‚N- Product line

Chikujee is developing an extensive pipeline of disease specific-contrasting agents for MRI imaging which includes further investigation with paramagnetic particles as well as several other promising iron oxide candidates. Key focus areas include an extensive array of MRI contrasting agent candidates for ultrasensitive detection of cancer and a developing cardiovascular portfolio.

1.2            CHÃŽKÃŽTÅ A- Product line

Chikujee Research has developed an extensive pipeline which includes further investigation with Paclitaxel and Docetaxel  as well as several other promising drug candidates. Key focus areas include an extensive array of oncology drug candidates and a developing cardiovascular portfolio. The following candidates are part of Chikujee’ accelerating pipeline.

Chikujee Therapeutics has chosen to work initially on building its pipeline with generic compounds that have been poorly adopted due to delivery issues. The Company has four internal drug delivery projects funded through internal and grant support:

1. BindiPRâ„¢,  a controlled release delivery vehicle for target specific delivery of protein based therapeutics to produce a more effective drug for treatment with minimal side effects.
2. BindiNAâ„¢, a controlled release delivery vehicle for target specific delivery of nucleic acid based therapeutics, RNAi, Oligos, gene therapy vectors etc., to provide effective disease specific treatment with minimal side effects.
3. BindiSMâ„¢ for the cell specific delivery of small molecules like chemotherapy agents to the target site
4. BindiGPâ„¢ a cell specific delivery of general purpose therapeutic agents to target tissues.